223 related articles for article (PubMed ID: 23627666)
1. Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder.
Keating C; Dawood T; Barton DA; Lambert GW; Tilbrook AJ
BMC Psychiatry; 2013 Apr; 13():124. PubMed ID: 23627666
[TBL] [Abstract][Full Text] [Related]
2. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
Knorr UB
Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
[TBL] [Abstract][Full Text] [Related]
3. Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder.
Hernández ME; Mendieta D; Martínez-Fong D; Loría F; Moreno J; Estrada I; Bojalil R; Pavón L
Eur Neuropsychopharmacol; 2008 Dec; 18(12):917-24. PubMed ID: 18805677
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder.
Ruhé HG; Khoenkhoen SJ; Ottenhof KW; Koeter MW; Mocking RJ; Schene AH
Psychoneuroendocrinology; 2015 Feb; 52():261-71. PubMed ID: 25544738
[TBL] [Abstract][Full Text] [Related]
5. Association of platelet function with depression and its treatment with sertraline in patients with chronic kidney disease: analysis of a randomized trial.
Jain N; Wan F; Kothari M; Adelodun A; Ware J; Sarode R; Hedayati SS
BMC Nephrol; 2019 Oct; 20(1):395. PubMed ID: 31664940
[TBL] [Abstract][Full Text] [Related]
6. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
[TBL] [Abstract][Full Text] [Related]
7. Cortisol, moderated by age, is associated with antidepressant treatment outcome and memory improvement in Major Depressive Disorder: A retrospective analysis.
Jain FA; Connolly CG; Reus VI; Meyerhoff DJ; Yang TT; Mellon SH; Mackin S; Hough CM; Morford A; Wolkowitz OM
Psychoneuroendocrinology; 2019 Nov; 109():104386. PubMed ID: 31382170
[TBL] [Abstract][Full Text] [Related]
8. Cortisol, oxytocin, and quality of life in major depressive disorder.
Tang AL; Thomas SJ; Larkin T
Qual Life Res; 2019 Nov; 28(11):2919-2928. PubMed ID: 31227958
[TBL] [Abstract][Full Text] [Related]
9. Cortisol response patterns in depressed women and their healthy daughters at risk: Comparison with healthy women and their daughters.
Gonul AS; Cetinkalp S; Tunay S; Polat I; Simsek F; Aksoy B; Kizilates G; Erdogan Y; Coburn KL
J Psychiatr Res; 2017 Feb; 85():66-74. PubMed ID: 27837659
[TBL] [Abstract][Full Text] [Related]
10. Higher serum DHEA concentrations before and after SSRI treatment are associated with remission of major depression.
Hough CM; Lindqvist D; Epel ES; Denis MS; Reus VI; Bersani FS; Rosser R; Mahan L; Burke HM; Wolkowitz OM; Mellon SH
Psychoneuroendocrinology; 2017 Mar; 77():122-130. PubMed ID: 28038403
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
Wu EQ; Yu AP; Lauzon V; Ramakrishnan K; Marynchenko M; Ben-Hamadi R; Blum S; Erder MH
Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
[TBL] [Abstract][Full Text] [Related]
12. Plasma serotonin levels are associated with antidepressant response to SSRIs.
Holck A; Wolkowitz OM; Mellon SH; Reus VI; Nelson JC; Westrin Å; Lindqvist D
J Affect Disord; 2019 May; 250():65-70. PubMed ID: 30831543
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment allostatic load and metabolic dysregulation predict SSRI response in major depressive disorder: a preliminary report.
Hough CM; Bersani FS; Mellon SH; Morford AE; Lindqvist D; Reus VI; Epel ES; Wolkowitz OM
Psychol Med; 2021 Sep; 51(12):2117-2125. PubMed ID: 32438932
[TBL] [Abstract][Full Text] [Related]
14. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L; Corcos M; Jeammet P
Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
[TBL] [Abstract][Full Text] [Related]
15. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.
Masiran R; Sidi H; Mohamed Z; Mohd Nazree NE; Nik Jaafar NR; Midin M; Das S; Mohamed Saini S
J Sex Med; 2014 Apr; 11(4):1047-1055. PubMed ID: 24533444
[TBL] [Abstract][Full Text] [Related]
16. Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression.
Bi Y; Ren D; Guo Z; Ma G; Xu F; Chen Z; An L; Zhang N; Ji L; Yuan F; Liu L; Hou B; Yang F; Yu S; Yi Z; Xu Y; He L; Sun X; Dong Z; Wu S; Zhao L; Cai C; Li X; Yu T; Shi Y; He G
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110036. PubMed ID: 32702381
[TBL] [Abstract][Full Text] [Related]
17. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
18. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
[TBL] [Abstract][Full Text] [Related]
19. Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study.
Rudzki L; Ostrowska L; Pawlak D; Małus A; Pawlak K; Waszkiewicz N; Szulc A
Psychoneuroendocrinology; 2019 Feb; 100():213-222. PubMed ID: 30388595
[TBL] [Abstract][Full Text] [Related]
20. Is increased antidepressant exposure a contributory factor to the obesity pandemic?
Lee SH; Paz-Filho G; Mastronardi C; Licinio J; Wong ML
Transl Psychiatry; 2016 Mar; 6(3):e759. PubMed ID: 26978741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
